Valuation: Mylan Inc

Market Cap 18.49B 16.19B 14.94B 13.94B 26.26B 1,749B 26.73B 179B 69.58B 863B 69.48B 67.93B 3,006B P/E 2026 *
58.1x
P/E 2027 * 25.2x
Enterprise Value 30.68B 26.85B 24.79B 23.12B 43.57B 2,901B 44.35B 297B 115B 1,431B 115B 113B 4,987B EV / Sales 2026 *
2.08x
EV / Sales 2027 * 1.96x
Free-Float
92.11%
Yield 2026 *
3.2%
Yield 2027 * 3.29%
Manager TitleAgeSince
Chief Executive Officer 63 01/04/2023
Director of Finance/CFO 59 08/05/2026
Chief Administrative Officer 42 19/08/2025
Director TitleAgeSince
Chairman 58 15/12/2023
Director/Board Member 70 16/11/2020
Director/Board Member 78 16/11/2020
Change 5-day change 1-year change 3-year change Capi.($)
-2.48%+8.34%+53.87%+155.75% 1,070B
-1.76%+6.23%+66.27%+53.44% 611B
-1.05%+7.19%+35.57%+86.77% 445B
+0.83%+4.18%+31.11%+23.88% 329B
-1.38%+3.75%+39.33%+25.04% 290B
+0.30%+2.56%+31.62%+40.64% 287B
-0.10%+2.23%-28.43%-42.77% 213B
+0.44%+4.35%+29.69%+63.10% 195B
+0.01%+1.03%+13.95%+63.93% 157B
Average -0.54%+5.04%+30.33%+52.20% 399.58B
Weighted average by Cap. -1.11%+6.67%+40.76%+77.26%

Financials

2026 *2027 *
Net sales 14.77B 12.93B 11.94B 11.14B 20.98B 1,397B 21.36B 143B 55.59B 689B 55.51B 54.27B 2,401B 15.04B 13.16B 12.15B 11.33B 21.35B 1,422B 21.74B 146B 56.58B 702B 56.5B 55.23B 2,444B
Net income 13M 11.38M 10.5M 9.8M 18.46M 1.23B 18.79M 126M 48.91M 606M 48.83M 47.74M 2.11B 498M 435M 402M 375M 707M 47.04B 719M 4.82B 1.87B 23.21B 1.87B 1.83B 80.87B
Net Debt 12.19B 10.67B 9.85B 9.19B 17.31B 1,152B 17.62B 118B 45.86B 569B 45.79B 44.76B 1,981B 11.03B 9.66B 8.91B 8.31B 15.66B 1,043B 15.94B 107B 41.5B 515B 41.44B 40.52B 1,793B
Logo Mylan Inc
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-